Actively Recruiting
Open-Label Phase 3 Study Evaluating Benralizumab Safety and Effects in Children With Rare Eosinophilic Diseases
Led by AstraZeneca · Updated on 2026-10-28
14
Participants Needed
15
Research Sites
64 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and effectiveness of benralizumab in children with rare eosinophilic diseases. This open-label, multicenter Phase 3 study includes pediatric participants with eosinophilic granulomatosis with polyangiitis EGPA and hypereosinophilic syndrome HES, with potential for additional eosinophilic disease groups in future amendments. Participants will receive benralizumab as a subcutaneous injection every four weeks for 52 weeks. Dosing depends on weight children weighing 35 kg or more receive one dose, while those under 35 kg receive a different dose. After completing the first year, participants may continue treatment in an extension period for at least another year, with ongoing safety monitoring following the last dose. Throughout the study, participants will undergo screening for eligibility, followed by regular assessments including blood tests to measure benralizumab levels and eosinophil counts, monitoring for adverse events, and evaluations of disease remission and flare-ups. Additional safety tests and questionnaires will be conducted at scheduled visits. The total participation time includes screening, 52 weeks of treatment, and at least 52 weeks of extension with safety follow-up.
CONDITIONS
Brief Title
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here